Literature DB >> 22846048

Patient and parent preferences for immunoglobulin treatments: a conjoint analysis.

Ateesha F Mohamed1, Vikram Kilambi, Michelle P Luo, Ravi G Iyer, Josephine M Li-McLeod.   

Abstract

OBJECTIVES: The purpose was to quantify patient and parent preferences for administration attributes of immunoglobulin (IG) treatments; and determine which administration attributes were most important to users of IG treatment and whether patients and parents have similar preferences for administration attributes.
METHODS: US adult patients and parents of children with a self-reported physician diagnosis of a primary immunodeficiency disorder completed a best-practice web-enabled choice-format conjoint survey that presented a series of 12 choice questions, each including a pair of hypothetical IG-treatment profiles. After reviewing current therapies, each profile was defined by mode of administration, frequency, location, number of needle sticks, and treatment duration. Before answering the choice questions, respondents were told to assume all treatments worked equally well. Choice questions were based on a D-efficient experimental design. Preference weights for attribute levels were estimated using random-parameters logit for each sample (adult patients and parents). Tests were performed to determine potential interactions among the administration attributes. All respondents provided online informed consent.
RESULTS: In total, 252 patients and 66 parents completed the choice questions appropriately. Overall, both groups preferred a home setting, monthly frequency, fewer needle sticks, and shorter treatment durations of IG treatment relative to alternative choices (p<0.05). Mode of administration was the least important attribute to both samples; however, parents strongly preferred self-administration to an appointment with a healthcare professional (p<0.05), whereas patients slightly preferred self-administration but were indifferent to the two modes. LIMITATIONS: Respondents evaluate hypothetical treatments and differences can arise between stated and actual choices.
CONCLUSIONS: Considering the hypothetical treatments evaluated, IG treatments that provide the option of a home setting, monthly frequency, fewer needle sticks, and shorter treatment durations may address the needs of both patients and parents. Patients and parents have different preferences for administration attributes of IG treatments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22846048     DOI: 10.3111/13696998.2012.716804

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  9 in total

Review 1.  Discrete choice experiments in health economics: a review of the literature.

Authors:  Michael D Clark; Domino Determann; Stavros Petrou; Domenico Moro; Esther W de Bekker-Grob
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

2.  Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy.

Authors:  Richard L Wasserman; Diane Ito; Yan Xiong; Xiaolan Ye; Patrick Bonnet; Josephine Li-McLeod
Journal:  J Clin Immunol       Date:  2017-02-03       Impact factor: 8.317

3.  Patient and physician preferences for attributes of biologic medications for severe asthma.

Authors:  Heather L Gelhorn; Zaneta Balantac; Christopher S Ambrose; Yen N Chung; Brian Stone
Journal:  Patient Prefer Adherence       Date:  2019-07-25       Impact factor: 2.711

4.  Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.

Authors:  Clémence Perraudin; Aline Bourdin; Alex Vicino; Thierry Kuntzer; Olivier Bugnon; Jérôme Berger
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

Review 5.  Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review.

Authors:  Paul M Overton; Natalie Shalet; Fabian Somers; Jeffrey A Allen
Journal:  Patient Prefer Adherence       Date:  2021-04-19       Impact factor: 2.711

6.  Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy.

Authors:  Juan Marcos Gonzalez; Mark Ballow; Angelyn Fairchild; Michael Chris Runken
Journal:  Front Immunol       Date:  2022-02-04       Impact factor: 7.561

7.  Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment.

Authors:  Teresa Espanol; Johan Prevot; Jose Drabwell; Seema Sondhi; Laurence Olding
Journal:  Patient Prefer Adherence       Date:  2014-05-02       Impact factor: 2.711

8.  What Is the Burden of Immunoglobulin Replacement Therapy in Adult Patients With Primary Immunodeficiencies? A Systematic Review.

Authors:  Georgina L Jones; Katharina S Vogt; Duncan Chambers; Mark Clowes; Anna Shrimpton
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

9.  Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.

Authors:  Christine Anterasian; Richard Duong; Peg Gruenemeier; Carol Ernst; Jessica Kitsen; Bob Geng
Journal:  J Clin Immunol       Date:  2019-11-01       Impact factor: 8.542

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.